Vor Biopharma Inc

NASDAQ VOR

Data sourced from iex and EODHD
Download Data

Vor Biopharma Inc Income Statement 2019 - 2024

This table shows the Income Statement for Vor Biopharma Inc going from 2019 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31
Revenue
M 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Cost of Revenue
M 1 1 2 1 3 3 - - - - - - - - - - - -
Gross Profit
M -1 11 -2 -1 -3 -3 - - - - - - - - - - - -
Operating Expenses
M 31 39 33 31 28 22 - - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 8 7 8 8 9 8 7 6 8 6 6 5 5 4 4 2 2 1
Research and Development (R&D) Expenses
M 24 21 28 24 22 17 17 15 15 13 13 13 9 11 8 6 6 3
Other Operating Expenses
M -1 11 -2 -1 -3 -3 - - - - - - - - - - - -
Costs and Expenses
M 30 26 33 31 28 22 - - - - - - - - - - - -
Operating Income
M -32 -28 -35 -32 -30 -25 -24 -22 -23 -18 -19 -18 -14 -16 -12 -8 -8 -4
Interest Expense
M - 2 - - -2 1 0 0 0 - - - - 0 - - - 0
Non-operating Income/Expense
M 2 2 2 2 2 1 0 0 0 69 0 0 0 43 - - 0 0
EBT
M -31 -26 -33 -30 -28 -24 -24 -22 -23 -18 -19 -18 -14 -16 -12 -8 -8 -4
Income Tax Provision
M - 1 1 - -2 -1 0 0 0 69 - - - 43 - - - 0
Income after Tax
M - -27 -35 - -26 -23 -23 -22 -23 -87 - - - -59 - - - -4
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 1 2 2 1 1 -
Net Income
M - - - -30 -28 -24 -24 -22 -23 -18 -19 -18 -15 -18 -14 -9 -9 -
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 68,030,966.00 67,891,311.00 67,607,713.00 67,033,150.00 66,265,703.00 39,551,420.00 38,009,022.00 37,437,063.00 37,293,438.00 36,934,311.00 36,934,311.00 36,843,087.00 22,263,994.00 22,263,994.00 12,208,211.00 12,208,211.00 12,208,211.00 12,208,211.00
EBITDA
M -31 -27 -35 -29 -30 -24 -23 -21 -22 -18 -18 -18 -13 -15 -12 -8 -8 -4
Depreciation and Amortization
M 1 1 -1 3 1 1 1 1 0 0 0 0 0 0 0 0 0 0
EBIT
M -32 -28 -34 -32 -30 -25 -24 -22 -23 -18 -19 -18 -14 -16 -12 -8 -8 -4
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -2.15 -4.29 - 7.00 4.23 1.32 0.61 0.28 -377.49 - - - -276.68 - - - -0.90
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -
Gross Profit Margin
% - 92.70 - - - - - - - - - - - - - - - -
Operating Income Margin
% - -230.03 - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -222.74 - - - - - - - - - - - - - - - -
EBIT Ratio
% - -230.03 - - - - - - - - - - - - - - - -
EBT Ratio
% - -214.80 - - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email